Want to see IN:WANBURY full AI Analyst Report?
Top Page
Wanbury Limited
(WANBURY)
Select Model
Select Model
Rating:49Neutral
Price Target:
₹238.00
▼(-28.42% Downside)
Action:Reiterated
Date:09/12/26
The score is held back primarily by weak cash conversion and negative free cash flow alongside still-elevated leverage, which creates funding and execution risk despite improved profitability. Technicals also indicate a bearish setup with the price below key moving averages and weak momentum. Valuation is a partial offset due to a moderate P/E.
Positive Factors
Diversified pharmaceutical model
The combination of formulations and API operations gives Wanbury multiple revenue channels across branded or generic medicines and business-to-business supplies. Domestic and export exposure can broaden market access and reduce reliance on one product category or geography over the next several quarters.
Negative Factors
Weak cash conversion
Minimal operating cash flow alongside healthy reported earnings shows that accounting profits are not converting effectively into cash. Persistently negative free cash flow can increase dependence on external funding, limit reinvestment capacity, and heighten execution risk if working capital or spending remains heavy.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified pharmaceutical model
The combination of formulations and API operations gives Wanbury multiple revenue channels across branded or generic medicines and business-to-business supplies. Domestic and export exposure can broaden market access and reduce reliance on one product category or geography over the next several quarters.
Read all positive factors
Wanbury Limited (WANBURY) vs. iShares MSCI India ETF (INDA)
Market Cap
₹7.80B
Dividend Yield1.2%
Average Volume (3M)28.14K
Price to Earnings (P/E)12.9
Beta (1Y)1.80
Revenue Growth3.63%
EPS Growth24.22%
CountryIN
Employees1,200
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)17.29
Shares Outstanding34,966,927
10 Day Avg. Volume13,890
30 Day Avg. Volume28,145
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)4.96
Price to Sales (P/S)1.10
P/FCF Ratio-12.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)24.2
Revenue Forecast (FY)₹8.76B
Wanbury Limited Business Overview & Revenue Model
Company Description
Wanbury Limited is an Indian pharmaceutical company engaged in the development, manufacturing, and commercialization of both finished drug products (formulations) and active pharmaceutical ingredients (APIs). The company's diverse range of formula...
How the Company Makes Money
Wanbury Limited makes money by selling pharmaceutical products across two core business lines: (1) Finished-dosage formulations (medicines sold as tablets, capsules, etc.) and (2) Active pharmaceutical ingredients (APIs) supplied to other drug man...
Wanbury Limited Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
50
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Jun 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.53B | 6.50B | 6.00B | 5.74B | 4.98B | 5.11B |
| Gross Profit | 2.65B | 2.40B | 3.05B | 2.65B | 1.89B | 2.04B |
| EBITDA | 955.38M | 1.04B | 798.13M | 985.49M | 234.91M | 1.13B |
| Net Income | 558.87M | 661.35M | 305.30M | 559.56M | -103.96M | 814.74M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 5.18B | 4.14B | 3.43B | 3.04B | 3.53B |
| Cash, Cash Equivalents and Short-Term Investments | 76.32M | 76.32M | 150.63M | 34.00M | 14.94M | 226.56M |
| Total Debt | 0.00 | 2.24B | 1.77B | 1.16B | 1.09B | 1.08B |
| Total Liabilities | -1.44B | 3.73B | 3.55B | 3.16B | 3.36B | 3.76B |
| Stockholders Equity | 1.44B | 1.44B | 592.72M | 279.41M | -61.54M | -234.20M |
Cash Flow | ||||||
| Free Cash Flow | -247.74M | -568.35M | -229.26M | -134.45M | 71.69M | 308.65M |
| Operating Cash Flow | -56.53M | 27.76M | 261.02M | 39.78M | 197.97M | 405.23M |
| Investing Cash Flow | -152.68M | -571.12M | -511.74M | -166.25M | -88.38M | 5.87M |
| Financing Cash Flow | 213.44M | 518.87M | 257.33M | 145.53M | -319.91M | -285.85M |
Wanbury Limited Technical Analysis
Negative
332.50
Price Trends
275.88
Negative
272.39
Negative
255.76
Negative
Market Momentum
-12.63
Positive
28.37
Positive
10.02
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WANBURY, the sentiment is Negative. The current price of 332.5 is above the 20-day moving average (MA) of 246.85, above the 50-day MA of 275.88, and above the 200-day MA of 255.76, indicating a bearish trend. The MACD of -12.63 indicates Positive momentum. The RSI at 28.37 is Positive, neither overbought nor oversold. The STOCH value of 10.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:WANBURY.
Wanbury Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹15.04B | 33.59 | ― | 1.65% | 3.87% | -25.38% | |
78 Outperform | ₹12.15B | 12.56 | ― | 0.30% | 10.20% | 11.70% | |
64 Neutral | ₹9.36B | 21.20 | ― | 1.61% | 9.70% | 21.04% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | ₹6.78B | 21.69 | ― | 0.40% | 14.04% | 2.57% | |
50 Neutral | ₹7.26B | 165.26 | ― | 0.15% | 7.55% | -57.19% | |
49 Neutral | ₹7.80B | 12.88 | ― | 1.20% | 3.63% | 24.22% |
* General Sector Average
IN:WANBURY
Wanbury Limited
223.15
-26.20
-10.51%
IN:JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd.
228.00
-6.81
-2.90%
IN:KILITCH
Kilitch Drugs (India) Limited
193.80
17.58
9.97%
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
606.40
57.56
10.49%
IN:ZIMLAB
Zim Laboratories Ltd.
135.30
59.72
79.02%
IN:ANUHPHR
Anuh Pharma Limited
93.39
9.10
10.79%
Wanbury Limited Corporate Events
Wanbury Gains USFDA DMF Clearance for Metformin API, Bolstering Global Expansion
Jul 30, 2026
Wanbury Limited announced that it has received a “No DMF deficiency” communication from the U.S. Food and Drug Administration for multiple ANDAs that use its Metformin HCl API in different formulations, indicating full compliance of it...
Wanbury says USFDA audit at Tanuku plant poses no material business impact
Jul 22, 2026
Wanbury Limited has reported that the U.S. Food and Drug Administration has completed a routine current Good Manufacturing Practices inspection at its Tanuku manufacturing facility in Andhra Pradesh. The inspection, conducted from July 13 to July ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.